| 
                    Name | 
                         Bambuterol 
                     | 
                
| Molecular Formula | C18H29N3O5 | |
| IUPAC Name* | 
                         [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate 
                     | 
                |
| SMILES | 
                         CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O 
                     | 
                |
| InChI | 
                         InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3 
                     | 
                |
| InChIKey | 
                         ANZXOIAKUNOVQU-UHFFFAOYSA-N 
                     | 
                |
| Synonyms | 
                         Bambuterol; 81732-65-2; Bambec; Bambuterolum; Bambuterol (INN); CHEBI:553827; [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; Y1850G1OVC; (+/-)-Bambuterol;KWD-2183; (+-)-5-(2-(tert-Butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); Bambuterolum [Latin]; Oxeol; BAMBUTEROL [INN]; KWD-2183; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate); (+/-)-5-(2-(tert-butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate); terbutaline bisdimethylcarbamate; Bambuterol [INN:BAN]; UNII-Y1850G1OVC; terbutaline bis(dimethylcarbamate); BAMBUTEROL [MI]; Prestwick0_000361; Prestwick1_000361; Prestwick2_000361; Prestwick3_000361; SCHEMBL4431; BAMBUTEROL [WHO-DD]; BSPBio_000481; MLS002153785; SPBio_002402; BPBio1_000531; CHEMBL521589; GTPL6601; DTXSID5048550; GLXC-25236; HMS2089J18; HMS2230O15; HMS3373N13; BCP21793; BDBM50235800; STK643808; AKOS005574764; CS-3157; DB01408; ( inverted exclamation markA)-Bambutero; ( inverted exclamation markA)-Bambuterol; NCGC00179546-01; NCGC00179546-02; AC-35438; HY-17501; SMR001233168; SBI-0207028.P001; FT-0602901; D07377; 732B652; A840189; L004435; Q3633651; SR-05000001470-1; BRD-A17462676-003-03-3; BRD-A17462676-003-06-6; (RS)-5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diyl bis(dimethylcarbamate); 5-(2-(tert-butylamino)-1-hydroxyethyl)-1,3-phenylene bis(dimethylcarbamate); [3-[2-(tert-butylamino)-1-oxidanyl-ethyl]-5-(dimethylcarbamoyloxy)phenyl] N,N-dimethylcarbamate; N,N-dimethylcarbamic acid [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-[dimethylamino(oxo)methoxy]phenyl] ester 
                     | 
                |
| CAS | 81732-65-2 | |
| PubChem CID | 54766 | |
| ChEMBL ID | CHEMBL521589 | 
Chemical Classification: | 
                    
                        
  | 
                    
                        
                            
                     | 
                
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | 
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | 
| Molecular Weight: | 367.4 | ALogp: | 1.2 | 
| HBD: | 2 | HBA: | 6 | 
| Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted | 
| Polar Surface Area: | 91.3 | Aromatic Rings: | 1 | 
| Heavy Atoms: | 26 | QED Weighted: | 0.831 | 
| Caco-2 Permeability: | -4.793 | MDCK Permeability: | 0.00001920 | 
| Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.865 | 
| Human Intestinal Absorption (HIA): | 1 | 20% Bioavailability (F20%): | 0.997 | 
| 30% Bioavailability (F30%): | 0.992 | 
| Blood-Brain-Barrier Penetration (BBB): | 0.166 | Plasma Protein Binding (PPB): | 37.89% | 
| Volume Distribution (VD): | 0.778 | Fu: | 74.54% | 
| CYP1A2-inhibitor: | 0.023 | CYP1A2-substrate: | 0.086 | 
| CYP2C19-inhibitor: | 0.024 | CYP2C19-substrate: | 0.969 | 
| CYP2C9-inhibitor: | 0.002 | CYP2C9-substrate: | 0.134 | 
| CYP2D6-inhibitor: | 0.724 | CYP2D6-substrate: | 0.753 | 
| CYP3A4-inhibitor: | 0.033 | CYP3A4-substrate: | 0.915 | 
| Clearance (CL): | 7.92 | Half-life (T1/2): | 0.878 | 
| hERG Blockers: | 0.122 | Human Hepatotoxicity (H-HT): | 0.006 | 
| Drug-inuced Liver Injury (DILI): | 0.039 | AMES Toxicity: | 0.068 | 
| Rat Oral Acute Toxicity: | 0.965 | Maximum Recommended Daily Dose: | 0.938 | 
| Skin Sensitization: | 0.315 | Carcinogencity: | 0.037 | 
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 | 
| Respiratory Toxicity: | 0.937 | 
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004204 | ![]()  | 
                    0.245 | D07XYV | ![]()  | 
                    1.000 | ||
| ENC000658 | ![]()  | 
                    0.245 | D0M8RC | ![]()  | 
                    0.392 | ||
| ENC001392 | ![]()  | 
                    0.241 | D01JFT | ![]()  | 
                    0.385 | ||
| ENC001382 | ![]()  | 
                    0.240 | D0X5NX | ![]()  | 
                    0.349 | ||
| ENC000695 | ![]()  | 
                    0.233 | D0AY7K | ![]()  | 
                    0.330 | ||
| ENC003608 | ![]()  | 
                    0.228 | D0K5CB | ![]()  | 
                    0.329 | ||
| ENC000071 | ![]()  | 
                    0.220 | D02ZJI | ![]()  | 
                    0.329 | ||
| ENC002963 | ![]()  | 
                    0.216 | D06RUL | ![]()  | 
                    0.328 | ||
| ENC006118 | ![]()  | 
                    0.215 | D0WY5Q | ![]()  | 
                    0.318 | ||
| ENC003377 | ![]()  | 
                    0.214 | D08USJ | ![]()  | 
                    0.294 | ||